EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)
A Phase III Randomised, Double-blind Trial to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg Compared to Placebo, in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)
Sponsor: Boehringer Ingelheim
This PHASE3 trial investigates Heart Failure and is currently completed. Boehringer Ingelheim leads this study, which shows 58 recorded versions since 2017 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
58 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE3
-
Nov 2025 — Feb 2026 [monthly]
Completed PHASE3
-
Oct 2025 — Nov 2025 [monthly]
Completed PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
▶ Show 53 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jul 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2021 — Jul 2022 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
May 2021 — Jun 2021 [monthly]
Active Not Recruiting PHASE3
-
Apr 2021 — May 2021 [monthly]
Active Not Recruiting PHASE3
-
Mar 2021 — Apr 2021 [monthly]
Active Not Recruiting PHASE3
-
Feb 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Nov 2020 — Dec 2020 [monthly]
Active Not Recruiting PHASE3
-
Oct 2020 — Nov 2020 [monthly]
Active Not Recruiting PHASE3
-
Sep 2020 — Oct 2020 [monthly]
Active Not Recruiting PHASE3
-
Aug 2020 — Sep 2020 [monthly]
Active Not Recruiting PHASE3
-
Jul 2020 — Aug 2020 [monthly]
Active Not Recruiting PHASE3
-
Jun 2020 — Jul 2020 [monthly]
Active Not Recruiting PHASE3
-
May 2020 — Jun 2020 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Apr 2020 — May 2020 [monthly]
Recruiting PHASE3
-
Mar 2020 — Apr 2020 [monthly]
Recruiting PHASE3
-
Feb 2020 — Mar 2020 [monthly]
Recruiting PHASE3
-
Jan 2020 — Feb 2020 [monthly]
Recruiting PHASE3
-
Dec 2019 — Jan 2020 [monthly]
Recruiting PHASE3
-
Nov 2019 — Dec 2019 [monthly]
Recruiting PHASE3
-
Oct 2019 — Nov 2019 [monthly]
Recruiting PHASE3
-
Sep 2019 — Oct 2019 [monthly]
Recruiting PHASE3
-
Aug 2019 — Sep 2019 [monthly]
Recruiting PHASE3
-
Jul 2019 — Aug 2019 [monthly]
Recruiting PHASE3
-
Jun 2019 — Jul 2019 [monthly]
Recruiting PHASE3
-
May 2019 — Jun 2019 [monthly]
Recruiting PHASE3
-
Apr 2019 — May 2019 [monthly]
Recruiting PHASE3
-
Mar 2019 — Apr 2019 [monthly]
Recruiting PHASE3
-
Feb 2019 — Mar 2019 [monthly]
Recruiting PHASE3
-
Jan 2019 — Feb 2019 [monthly]
Recruiting PHASE3
-
Dec 2018 — Jan 2019 [monthly]
Recruiting PHASE3
-
Nov 2018 — Dec 2018 [monthly]
Recruiting PHASE3
-
Oct 2018 — Nov 2018 [monthly]
Recruiting PHASE3
-
Sep 2018 — Oct 2018 [monthly]
Recruiting PHASE3
-
Aug 2018 — Sep 2018 [monthly]
Recruiting PHASE3
-
Jul 2018 — Aug 2018 [monthly]
Recruiting PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE3
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE3
-
Apr 2018 — May 2018 [monthly]
Recruiting PHASE3
-
Mar 2018 — Apr 2018 [monthly]
Recruiting PHASE3
-
Feb 2018 — Mar 2018 [monthly]
Recruiting PHASE3
-
Jan 2018 — Feb 2018 [monthly]
Recruiting PHASE3
-
Dec 2017 — Jan 2018 [monthly]
Recruiting PHASE3
-
Nov 2017 — Dec 2017 [monthly]
Recruiting PHASE3
-
Oct 2017 — Nov 2017 [monthly]
Recruiting PHASE3
-
Aug 2017 — Oct 2017 [monthly]
Recruiting PHASE3
-
Jul 2017 — Aug 2017 [monthly]
Recruiting PHASE3
-
Jun 2017 — Jul 2017 [monthly]
Recruiting PHASE3
-
May 2017 — Jun 2017 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Apr 2017 — May 2017 [monthly]
Not Yet Recruiting PHASE3
-
Mar 2017 — Apr 2017 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Boehringer Ingelheim
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aachen, Germany , Adelaide, Australia , Aguascalientes, Mexico , Ahmedabad, India , Aichi, Kasugai, Japan , Aichi, Nagoya, Japan , Albany, United States , Alberton, South Africa , Almelo, Netherlands , Alpena, United States and 458 more locations